
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Analysis of West Pharmaceutical Services (WST) amidst lowered guidance, a securities investigation, and declining profit margins. Key insights for investors.
Analysis of West Pharmaceutical Services, Inc. (WST) amid securities fraud investigations and revised guidance. Dive into market reactions and future outlook.
West Pharmaceutical Services navigates uncertainty amid lowered guidance and a securities probe. Key is understanding Q4 results, industry trends, and analyst ratings.
West Pharmaceutical Services faces scrutiny after revising its 2025 guidance downwards, triggering securities fraud investigations. Investors should remain cautious.
West Pharmaceutical Services faces dividend pressure amidst market turbulence, securities fraud allegations, and lowered guidance. A detailed analysis of WST's challenges and prospects.
In-depth analysis of West Pharma's Q4 earnings and 2025 guidance, driven by currency headwinds, destocking trends, and strategic capacity expansion.
Detailed analysis reveals robust Q4 earnings but 2025 guidance challenges from strong currency headwinds and client inventory reductions.